Kristen Ambrose - 09 Feb 2024 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
09 Feb 2024
Net transactions value
-$827,249
Form type
4
Filing time
13 Feb 2024, 16:48:51 UTC
Previous filing
08 Feb 2024
Next filing
27 Feb 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability $249,839 -591 -5.1% $422.74 11,050 09 Feb 2024 Direct
transaction VRTX Common Stock Sale $577,410 -1,374 -12% $420.24 9,676 12 Feb 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Ms.Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023.